Location History:
- Uppsala, SE (2011)
- Stockholm, SE (2005 - 2013)
Company Filing History:
5 out of 15 
2 out of 371 
1 out of 40 
Years Active: 2005-2013
Title: The Innovations of Mathias Alterman
Introduction
Mathias Alterman is a prominent inventor based in Stockholm, Sweden, known for his contributions to the field of pharmaceuticals. With a remarkable portfolio of 8 patents, Alterman has made significant strides in developing compounds that target the angiotensin II receptor, addressing various gastrointestinal and cardiovascular conditions.
Latest Patents
Among his latest innovations are two notable patents:
1. **Bicyclic Angiotensin II Agonists** - This patent describes a compound with a specific formula and its pharmaceutically-acceptable salts, which are effective selective agonists of the AT2 receptor. These compounds hold potential for treating gastrointestinal conditions such as dyspepsia, irritable bowel syndrome (IBS), and myocardial oxygen flow (MOF), as well as cardiovascular disorders.
2. **Tricyclic Compounds Useful as Angiotensin II Agonists** - Similar to his previous patent, this includes compounds with a particular formula that serve as selective agonists of the AT2 receptor. The applications of these compounds extend to the treatment of the same gastrointestinal and cardiovascular issues.
Career Highlights
Mathias Alterman has a noteworthy career with experience at reputable companies such as Vicore Pharma AB and GE Healthcare Bio-Sciences AB. His work at these organizations has played a crucial role in advancing pharmaceutical research and innovation.
Collaborations
Throughout his career, Alterman has collaborated with distinguished professionals in the field. Notable coworkers include Anders Rudolf Hallberg and Andreas Axen, with whom he has shared insights and expertise in developing groundbreaking pharmaceutical solutions.
Conclusion
In summary, Mathias Alterman's contributions to pharmaceutical inventions are marked by his innovative patents and collaborative spirit. His work stands out for its potential to provide significant health benefits, paving the way for future advancements in the treatment of critical gastrointestinal and cardiovascular disorders.